Trials / Completed
CompletedNCT06087003
Pediatric Induction Therapy in Kidney Transplantation
Induction Therapy of Thymoglobulin Versus Basiliximab in the Prevention of Acute Rejection After Pediatric Kidney Transplantation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 958 (actual)
- Sponsor
- Gang Chen · Academic / Other
- Sex
- All
- Age
- 1 Month – 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to compare the efficacy of two most commonly used induction therapy for the prevention of acute rejection (AR) after renal transplantation in children. The main question it aims to answer is: Is basiliximab (anti-CD25 monoclonal antibody) induction therapy effective and safe in preventing AR after kidney transplantation in children compared with anti-thymoglobulin polyclonal antibodies induction therapy? The transplant and follow-up data of participants will be retrospectively collected. Researchers will compare the rate of AR to see if basiliximab (anti-CD25 monoclonal antibody) induction therapy is a better option for certain pediatric kidney transplant recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Basiliximab Injection | As an induction treatment for kidney transplantation |
| DRUG | rabbit ATG | As an induction treatment for kidney transplantation |
Timeline
- Start date
- 2013-03-03
- Primary completion
- 2022-07-27
- Completion
- 2023-09-30
- First posted
- 2023-10-17
- Last updated
- 2023-10-17
Locations
5 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06087003. Inclusion in this directory is not an endorsement.